MetaCap

Adagene (ADAG) vs Zentalis Pharmaceuticals (ZNTL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Zentalis Pharmaceuticals (ZNTL) has outperformed Adagene (ADAG) over the past year, gaining 1.5% versus a loss of 2.2%. Over five years, ADAG leads with a -79.7% price change compared with -98.2% for ZNTL. Zentalis Pharmaceuticals is the larger company by market cap ($133.6 million vs $118.2 million), about 1.1 times the size, while Adagene is growing revenue faster (+7332.8% vs -100.0%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADAG-2.22%ZNTL+1.49%
+414%+188%-38%
Nov 21, 20251 yearNov 20, 2026
ADAG-81.97%ZNTL-98.25%
+14%-45%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADAG versus ZNTL key metrics
MetricADAGZNTL
Share price$1.76$1.36
Market cap$118.17M$133.64M
1-day change-12.44%0.00%
YTD return-6.88%+0.74%
1-year return-2.22%+1.49%
5-year return-79.75%-98.21%
EPS (TTM)$-0.37$-1.90
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.67M$0
Revenue growth (YoY)+7332.76%-100.00%
Net income (latest FY)$-17.61M$-137.06M
Operating margin-279.48%—
Net margin-229.56%—
52-week high$4.85$6.95
52-week low$1.27$1.30
Distance from 52-week high-63.71%-80.43%
Analyst consensusnonestrong_buy
Avg. price target upside+463.07%+447.06%
Average volume348.81K1.26M
Shares outstanding67.14M98.27M
Employees128106
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Adagene grew revenue faster in its latest fiscal year (+7332.76% vs -100.00%).

About Adagene

ADAG stock →

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees

About Zentalis Pharmaceuticals

ZNTL stock →

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.

Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees

ADAG vs ZNTL FAQ

Which is bigger, Adagene or Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (ZNTL) is larger, with a market capitalization of $133.64M compared with $118.17M for Adagene (ADAG).

Which stock has performed better over the past year, ADAG or ZNTL?

ZNTL returned +1.49% over the past 12 months, compared with -2.22% for ADAG (price return, excluding dividends). Past performance does not predict future results.

Are Adagene and Zentalis Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons